Strategies to manage hepatitis C virus (HCV) disease burden

Heiner Wedemeyer, Ann Sofi Duberg, Maria Asuncion Buti, William M C Rosenberg, Sona Frankova, Gamal Esmat, Necati Ormeci, H Van Vlierberghe, Michael Gschwantler, Ulus Salih Akarca, Soo Aleman, Ismail Balik, T Berg, Florian K Bihl, M Bilodeau, A J Blasco, Carlos Eduardo Brandao-Mello, Philip Bruggmann, Filipe Calinas, J L CallejaHugo Cheinquer, P B Christensen, M Clausen, H S M Coelho, Markus Cornberg, Matthew E Cramp, Gregory J Dore, Wahid H Doss, Mohammed H El-Sayed, Gul Ergor, Chris Estes, K Falconer, J Felix, M L G Ferraz, P R Ferreira, Javier Garcia-Samaniego, J Gerstoft, Jose A Giria, Fernando Lopes Goncales, M Guimaraes Pessoa, Christophe Hezode, S J Hindman, H Hofer, P Husa, Ramazan Idilman, M Kaberg, Kelly Kaita, Achim Kautz, Sabahattin Kaymakoglu, Mel Krajden, H Krarup, Wim J Laleman, D Lavanchy, P Lazaro, R T Marinho, P Marotta, Stefan Mauss, Maria Cassia Jacintho Mendes-Correa, Christophe A Moreno, B Mullhaupt, Robert P Myers, V Nemecek, Anne Lindebo Holm Ovrehus, J Parkes, Kevork Minas Peltekian, Alnoor S Ramji, Homie A Razavi, N Reis, Stuart Keith Roberts, Francoise Roudot-Thoraval, Stephen D Ryder, Rui Sarmento-Castro, Christoph M Sarrazin, David Semela, M Sherman, Gamal Elsayed Shiha, J Sperl, Peter Starkel, R E Stauber, Alexander James V Thompson, P Urbanek, P Van Damme, I Van Thiel, Dominique M Vandijck, W Vogel, Imam A Waked, N Weis, Johannes Wiegand, Ayman Yosry, Amany Zekry, Francesco Negro, William Sievert, Erin E Gower

Research output: Contribution to journalArticleResearchpeer-review

182 Citations (Scopus)


The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10 , this analysis suggests it is possible to achieve elimination of HCV (defined as a >90 decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.
Original languageEnglish
Pages (from-to)60 - 89
Number of pages30
JournalJournal of Viral Hepatitis
Issue numberSupplement S1
Publication statusPublished - 2014

Cite this